|Mr. Jose Carmona||CFO & Treasurer||639.05k||N/A||1972|
|Mr. Jesper HÃ¸iland||Sr. Advisor||936.06k||N/A||1960|
|Dr. Charles Q. Morris||Chief Medical Officer||682.55k||N/A||1965|
|Mr. G. Kelly Martin||CEO, Pres & Director||N/A||N/A||1959|
|Dr. Stavros C. Manolagas||Founder & Member of the Scientific Advisory Board||N/A||N/A||N/A|
Radius Health, Inc., a biopharmaceutical company, develops and commercializes endocrine therapeutics in the areas of osteoporosis and oncology. The company markets TYMLOS, an anabolic agent for the treatment of postmenopausal women with osteoporosis. It is also developing abaloparatide-SC, which is in phase 3 clinical study for the treatment of osteoporosis in men; abaloparatide transdermal patch, a short-wear-time patch, that is in phase 3 clinical study to treat postmenopausal women with osteoporosis; Elacestrant (RAD1901), a selective estrogen receptor degrader, which is in phase 3 clinical study for the treatment of hormone receptor-positive breast cancer; and RAD140, a non-steroidal selective androgen receptor modulator, which is in phase 1A clinical study to treat metastatic breast cancer. The company has collaborations and license agreements with 3M Company; Ipsen Pharma SAS; Eisai Co. Ltd.; Duke University; Guardant Health, Inc.; and Teijin Limited. Radius Health, Inc. was founded in 2003 and is headquartered in Waltham, Massachusetts.
Radius Health, Inc.’s ISS Governance QualityScore as of December 8, 2019 is 6. The pillar scores are Audit: 2; Board: 7; Shareholder Rights: 6; Compensation: 7.